Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(931)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Nov 18, 2024 3:26pm
Yes, Bucky you are the smartest person ever!
That's right Bucky, I sure you have both a medical degree & a business degree. How elese could one qualify to openly trash the analysts? Then again, my quick resurch. You have posted
...more
(193)
•••
settoretire
X
View Profile
View Bullboard History
Comment by
settoretire
on Nov 18, 2024 2:51pm
RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Lower price predictions are due to who will be in charge of the FDA in the USA. If you, or anyone thing RFK is good for health, then let me sell you a bridge. More bad news coming. Wish it weren't
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 18, 2024 2:43pm
RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
I believe these analyst almost as much as I believe the pumpers on here. Trash.
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 18, 2024 2:42pm
RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Leede Financial lowered Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a research report on Wednesday, November 13th
(479)
•••
Peladawn
X
View Profile
View Bullboard History
Comment by
Peladawn
on Nov 18, 2024 2:19pm
RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Hey Bucky.....you forgot to mention this optimistic outlook by Raymond James....re-iterated $5.00 https://www.americanbankingnews.com/2024/11/16/fy2024-earnings-estimate-for-oncy-issued-by
...more
(85)
•••
CaseyL
X
View Profile
View Bullboard History
Comment by
CaseyL
on Nov 18, 2024 12:47pm
RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
Click bait title - nowhere in the actual article is the word pessimistic even found. And it's regarding earnings. We have no earnings. We have no revenue stream. Gotta love these low ball idiots
...more
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 18, 2024 11:51am
RE:RE:RE:RE:RE:How does Accelerated Approval work
Wainwright issues pessimistic outlook for oncy. Oh well. Maybe unnoteables worthless posts will help.
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 17, 2024 5:42pm
RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo
Hotani T, Mizuguchi H, Sakurai F. Systemically administered reovirus-induced downregulation of hypoxia inducible factor-1α in subcutaneous tumors. Mol Ther Oncolytics 2019 https://jitc.bmj.com
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 17, 2024 5:39pm
RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
Hotani et al. demonstrated that reovirus (pelareorep) reduces HIF-1α expression in hypoxic tumor fractions, contributing to the overall oncolytic effect by reducing transcription of HIF1α-responsive
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 17, 2024 4:39pm
RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
" The opportunity is enormous: Keytruda alone generated $25 billion last year across multiple indications. That still left room for rivals to generate blockbuster sales, with Bristol Myers
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 17, 2024 4:22pm
RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
November 14, 2024 - BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and secure full rights to a leading prospect in
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Nov 17, 2024 4:02pm
HDAC inhibitor resistant cells vulnerable to pelareorep
In a 2020 paper Islam et al. reported that their investigation revealed that HDAC inhibitor-resistant cells displayed enhanced vulnerability to reovirus replication and cell death in both in vitro and
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 17, 2024 3:07pm
RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo
In 2020, Groeneveldt et al. demonstrated that oncolytic reovirus can be effectively emplyed as an effective strategy to enhance the efficacy of CD3-bsAbs in immune-silent solid tumors. The
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 16, 2024 2:42pm
RE:RE:RE:Oncolytics Biotech Announces Key Progress & Upcoming Studies
ONCY's pelareorep in pancreatic cancer / Goblet 1 Phase 2 timeline: - June 2023 ONCY's pelareorep is selected for PanCan's Precision Promise Pivotal Phase 3 Platform Trial. - September
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden